4.7 Article

Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers

期刊

MARINE DRUGS
卷 19, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/md19010041

关键词

topsentinol L trisulfate; AMPK; CHK1; breast cancer; drug susceptibility

资金

  1. NIH [1U01CA164720-01, TW006671]
  2. Huntsman Cancer Institute (HCI) Breast Center of Excellence Award
  3. HCI Directors Translational Research Initiative
  4. National Institutes of Health [R01GM085601, U54CA209978]

向作者/读者索取更多资源

TLT, a trisulfated sterol identified from Marine Invertebrate Compound Library (MICL), shows increased efficacy against basal-like and claudin-low (BL-CL) breast cancers by inhibiting the activation of AMP-activated protein kinase (AMPK) and checkpoint kinase 1 (CHK1). Breast and bladder cancer are identified as the most sensitive to TLT based on a drug response gene-expression signature, while glioblastoma multiforme is the least sensitive.
Patients diagnosed with basal-like breast cancer suffer from poor prognosis and limited treatment options. There is an urgent need to identify new targets that can benefit patients with basal-like and claudin-low (BL-CL) breast cancers. We screened fractions from our Marine Invertebrate Compound Library (MICL) to identify compounds that specifically target BL-CL breast cancers. We identified a previously unreported trisulfated sterol, i.e., topsentinol L trisulfate (TLT), which exhibited increased efficacy against BL-CL breast cancers relative to luminal/HER2+ breast cancer. Biochemical investigation of the effects of TLT on BL-CL cell lines revealed its ability to inhibit activation of AMP-activated protein kinase (AMPK) and checkpoint kinase 1 (CHK1) and to promote activation of p38. The importance of targeting AMPK and CHK1 in BL-CL cell lines was validated by treating a panel of breast cancer cell lines with known small molecule inhibitors of AMPK (dorsomorphin) and CHK1 (Ly2603618) and recording the increased effectiveness against BL-CL breast cancers as compared with luminal/HER2+ breast cancer. Finally, we generated a drug response gene-expression signature and projected it against a human tumor panel of 12 different cancer types to identify other cancer types sensitive to the compound. The TLT sensitivity gene-expression signature identified breast and bladder cancer as the most sensitive to TLT, while glioblastoma multiforme was the least sensitive.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据